Search results for "Neurocognitive function"

showing 1 items of 1 documents

Intensive LDL-cholesterol lowering therapy and neurocognitive function

2017

The key lipid-lowering target is to achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) levels, usually by using statins. The new treatment strategies for lipid-lowering therapy include using proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as an exciting approach to reduce residual risk of cardiovascular diseases (CVD). However, concerns about possible adverse effects, including neurocognitive disorders, were issued by the Food and Drug Administration (FDA). The current disputable evidence does not allow definite conclusions as to whether statins contribute to, or cause, clinically meaningful cognitive impairment. Some evidence indicates a high rate of…

MaleApolipoprotein Emedicine.medical_specialtyStatinmedicine.drug_classNeurocognitive DisordersProprotein convertase subtilisin/kexin type 9030204 cardiovascular system & hematologyBioinformatics03 medical and health sciencesCognitionSex Factors0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLipid-lowering drugAnimalsDementiaLow-density lipoprotein cholesterolAge FactorPharmacology (medical)Adverse effectHypolipidemic AgentsPharmacologybusiness.industryPCSK9PCSK9 InhibitorsAge FactorsStatinCognitionCholesterol LDLmedicine.diseaseNeurocognitive functionResidual riskEndocrinologyFemalelipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessNeurocognitive030217 neurology & neurosurgeryPharmacology & Therapeutics
researchProduct